|
|
|
30.07.25 - 14:06
|
Merz Aesthetics Strengthens U.S. Commercial Leadership With Key Executive Hires (Business Wire)
|
|
|
RALEIGH, N.C.--(BUSINESS WIRE)--Merz Aesthetics, the world's largest dedicated medical aesthetics business, today announced two additions to its North America regional executive team: Chris Van Dyk, Vice President of U.S. Sales, and DJ Sethares, Vice President of U.S. Marketing. In their new roles, Van Dyk and Sethares will oversee all sales and marketing efforts, respectively, to drive growth across the Merz Aesthetics portfolio of brands in the United States.
Previously, Van Dyk served as Country Manager for Merz Aesthetics Canada, where he successfully led the organization through a period of strong growth and strategic transformation after joining in 2022. He brings more than 20 years of experience across the pharmaceutical and medical device industries, including prior senior commercial and leadership roles at global organizations including Johnson & Johnson, Bayer, and Alcon.
Throughout his career, Van Dyk has been recognized for raising organizational standards, fostering deep customer loyalty and...
|
|
|
29.07.25 - 15:01
|
Alcon Launches Dry-eye Drug Tryptyr In U.S (AFX)
|
|
|
WASHINGTON (dpa-AFX) - Alcon Inc. (ALC.SW) Tuesday said it has launched Tryptyr, indicated for the treatment of dry eye disease in the U.S.The drug was approved by the U.S. Food and Drug Administr......
|
|
|
|
|
08.07.25 - 16:48
|
Alcon′s Unity VCS Gets Health Canada Approval (AFX)
|
|
|
OTTAWA (dpa-AFX) - Alcon, Inc. (ALC) announced Tuesday that UNITY Vitreoretinal Cataract System (VCS) has received Health Canada approval. This innovation is the first to be introduced from Alcon'......
|
|
|
|
|
08.07.25 - 15:36
|
Alcon holt Julie Brewer in die Geschäftsleitung (Cash)
|
|
|
Kontaktlinsenhersteller - Per 9. Juli 2025 übernimmt Julie Brewer die Verantwortung für die weltweiten Franchisen im Rang eines Senior Vice President, wie der Augenheilkundespezialist am Dienstag mitteilte....
|
|
|
|
|
|
|
|
|
07.07.25 - 14:06
|
Alcon to Acquire LumiThera and Its Photobiomodulation Device for the Treatment of Early and Intermediate Dry Age-Related Macular Degeneration (AMD) (Business Wire)
|
|
|
LumiThera's photobiomodulation (PBM) device is the first and only technology that has demonstrated meaningful visual improvement with two years of treatments* in early and intermediate dry AMD patients1,2
Nearly 200 million people globally live with dry AMD, a progressive disease with no cure, and a leading cause of blindness in developed nations3,4
Alcon aims to expand PBM office-based treatment in approved markets, underscoring its commitment to people living with retinal diseases
GENEVA--(BUSINESS WIRE)--Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced its intention to acquire LumiThera, Inc., a leader in light-based innovations for ophthalmology, and its PBM device for the treatment of early and intermediate dry AMD.1 LumiThera's PBM is the only device that has demonstrated meaningful vision improvement compared to baseline for people living with early to intermediate dry AMD.2,* Dry AMD is a progressive disease typically treated in la...
|
|
|
|
|
|
|
|
|
|
|
|
|
30.05.25 - 13:48
|
US FDA approves Alcon′s Tryptyr ophthalmic solution for Dry Eye Disease (PBR)
|
|
|
Previously known as AR-15512, Tryptyr is a transient receptor potential melastatin 8 (TRPM8) receptor agonist that stimulates corneal sensory nerves to increase production of natural tears rapidly. It
The post US FDA approves Alcon's Tryptyr ophthalmic solution for Dry Eye Disease appeared first on Pharmaceutical Business review....
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
